Other kinase inhibitors and VEGF R antagonists that are in development and may be used in the present invention include tivozanib Aveo Pharmaecuticals; vatalanib Bayer Novartis; lucitanib Clovis Oncology; dovitinib TK1258, Novartis; Chiauanib Chipscreen Biosciences; CEP 11981 Cephalon; linifanib Abbott Laboratories; neratinib HKI 272, Puma Biotechnology; radotinib Supect, IY5511, II Yang Pharmaceuticals, S stromectol bed bugs
Other kinase inhibitors and VEGF R antagonists that are in development and may be used in the present invention include tivozanib Aveo Pharmaecuticals; vatalanib Bayer Novartis; lucitanib Clovis Oncology; dovitinib TK1258, Novartis; Chiauanib Chipscreen Biosciences; CEP 11981 Cephalon; linifanib Abbott Laboratories; neratinib HKI 272, Puma Biotechnology; radotinib Supect, IY5511, II Yang Pharmaceuticals, S stromectol bed bugs